Kodiak Sciences Inc.

KOD

$33.80

Updated: 22/09/2026, 23:31:00

Market Cap

$2.12B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for KOD

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

USD

NASDAQ

CEO: Victor Perlroth

Employees: 141

https://kodiak.com

Asset Summaries

Latest generated summaries for KOD

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for KOD.

Share price: $33.80
Market cap: $2.12B
Exchange: NASDAQ
Currency: USD
CEO: Victor Perlroth
Employees: 141
IPO date: 04/10/2018
Beta: 2.18
Last dividend: $0.00
Day range: $32.46 – $34.45
52-week range: $10.94 – $47.84
1-day performance: 4.26%
1-year performance: 208.96%
Current drawdown (1Y): -29.35%
CIK: 0001468748
CUSIP: 50015M109
ISIN: US50015M1099
Created: 07/12/2025, 04:58:58
Last update: 22/09/2026, 23:31:00

Track Kodiak Sciences Inc. with an AI analyst

See which prediction-market events move KOD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to KOD from your Railway `news_articles` table.

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Zacks Investment Research • STOCK • 04/06/2026, 14:07:09

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Zacks Investment Research • STOCK • 08/05/2026, 15:41:20

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

PRNewsWire • STOCK • 01/05/2026, 02:23:00

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Zacks Investment Research • STOCK • 30/04/2026, 14:31:29

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

Zacks Investment Research • STOCK • 01/04/2026, 15:46:10

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PRNewsWire • STOCK • 31/03/2026, 18:45:00

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Zacks Investment Research • STOCK • 27/03/2026, 14:11:12

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Reuters • STOCK • 26/03/2026, 09:12:38

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

Zacks Investment Research • STOCK • 06/02/2026, 13:35:23